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Iron supplementation in early life and chil d health
In this issue of The Lancet Global Health, Sant-Rayn Pasricha 
and colleagues report ﬁ ndings from a meta-analysis 
examining the eﬀ ects of daily iron supplementation 
on the health of young children. Eligibility included 
randomised controlled trials (RCTs) that provided 
intervention in the form of iron or a placebo to children 
within the age range of 4–23 months. The authors 
report on multiple outcomes relevant to programmes 
aimed at controlling anaemia in developing countries, 
namely: haematological and iron status, cognitive and 
psychomotor development, physical growth, safety, 
and other micronutrients. The haematological eﬀ ects 
of iron deﬁ ciency and supplementation have long been 
known, but, more recently, non-haematological ﬁ ndings 
of iron deﬁ ciency have been acknowledged. These non-
haematological outcomes are often subtle and, therefore, 
may be largely underestimated.
The strongest reported ﬁ ndings were for the 
haematology and iron status outcomes, for which 
increased haematology and iron status were seen in 
those supplemented with iron. Subgroup analyses 
were informative and consistent with previous ﬁ ndings 
that indicated greater increases in these outcomes for 
those who began the trial with the poorest iron status. 
Findings of no eﬀ ect of iron supplementation on 
cognitive and psychomotor development may seem 
counterintuitive, given the known necessity of iron 
for optimal brain processing.1 One interpretation is 
that studies need to be longer because diﬀ erences may 
not emerge until a later age. However, these ﬁ ndings 
are consistent with those of previous reports.2–4 The 
large volume of published animal studies detailing the 
neurological eﬀ ects of iron deﬁ ciency1 renders it foolish 
to conclude that iron is not necessary for brain processes 
in this age group, but these ﬁ ndings are a reminder of the 
many unanswered questions that we have with respect 
to this relation. Of concern are the ﬁ ndings of reduced 
length and weight gain and increased prevalence of 
fever in those receiving iron. These ﬁ ndings did become 
non-signiﬁ cant when only studies regarded to be at 
low risk for bias were included. However, the ﬁ nding of 
increased vomiting with iron supplementation was seen 
even in the one study with low risk of bias. It is possible 
that children who were iron deﬁ cient, anaemic, or both 
at baseline beneﬁ tted from supplementation whereas 
those who were iron suﬃ  cient at baseline experienced 
harm. Lack of stratiﬁ cation of analyses by baseline iron 
status makes this impossible to determine. Altered 
zinc status in those receiving combined iron and zinc 
supplementation has been reported previously but 
it should be remembered that zinc status of children 
supplemented with the combined nutrients is still 
higher than those who receive a placebo.
This paper contributes to the literature in multiple 
ways. First, the focus on this young age group is 
informative. Given the incredible rate of growth and 
the developmental changes occurring in this age group, 
coupled with the fact that the highest prevalence of 
iron-deﬁ ciency anaemia is found in children younger 
than 4 years (ranging from 7% in high-income 
countries to 76% in south Asia),5 it is imperative that 
we clearly understand the risks and beneﬁ ts of iron 
supplementation in this age group. It is also helpful that 
Pasricha and colleagues report on multiple outcomes on 
which policy is likely to be based. Most meta-analyses 
to date have not been as focused on one particular age 
group yet broad in the outcomes assessed. The authors’ 
inclusion criteria (conﬁ ned to RCTs in otherwise well, 
community, or outpatient children) helped to focus the 
analysis and allowed for better comparability across 
studies. Although this does not guarantee elimination 
of all potential confounders, it narrows the possibility. 
The clear assessment of risk of bias provided for each 
study and the multiple subgroup analyses allowed for 
better interpretability of the ﬁ ndings and are pieces 
frequently missing from previous analyses. 
Limitations of meta-analyses are often based on the 
strength of the data available. Only 26% of the eligible 
studies were judged to be at low risk of overall bias 
in this analysis. Other studies may have been at low 
risk for bias but failed to report information necessary 
for this determination. All RCTs have a methodology 
for randomisation and concealment of allocation 
and reporting such information will allow for better 
comparison across studies in the future. It is also 
imperative that future reports include information 
on adherence, preferably in a standardised manner. 
Future meta-analyses would also beneﬁ t from ﬁ ndings 
where data have been stratiﬁ ed by baseline iron status. 
Iron is an essential trace element required for growth, 
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development, and normal cellular functioning.6 
However, there is also considerable danger of toxicity 
with iron if excessive amounts accumulate in the body.7 
Although a ﬁ nely tuned feedback control system helps 
to limit the possibility of excessive accumulation, it 
is possible that various pathologies may alter this 
feedback, placing the individual at risk. Therefore, 
knowing the baseline iron status of an individual will 
aid in properly interpreting the research ﬁ ndings. As 
stated by Pasrich and colleagues, more RCTs of non-
haematological outcomes are needed to make deﬁ nitive 
conclusions as to the beneﬁ ts and harm of daily iron 
supplementation in this age group. Detailed reporting 
of ﬁ ndings that include stratiﬁ cation of results by 
baseline iron status will provide us with data needed to 
properly inform policy.
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